Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M6,496Revenue $M576Net Margin (%)4.3Z-Score8.1
Enterprise Value $M6,307EPS $0.2Operating Margin %14.2F-Score7
P/E(ttm))0Cash Flow Per Share $0.0Pre-tax Margin (%)6.2Higher ROA y-yY
Price/Book4.910-y EBITDA Growth Rate %0Quick Ratio7.8Cash flow > EarningsY
Price/Sales10.75-y EBITDA Growth Rate %0Current Ratio8.4Lower Leverage y-yY
Price/Cash Flow725y-y EBITDA Growth Rate %18.3ROA % (ttm)1.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)2.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M145ROI % (ttm)-2.4Gross Margin Increase y-yY

Gurus Latest Trades with ALKS

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALKSVanguard Health Care Fund 2014-03-31 Add0.19%$40.07 - $53.82
($47.32)
$ 44.11-7%Add 41.07%5,180,238
ALKSJohn Burbank 2014-03-31 Buy 0.01%$40.07 - $53.82
($47.41)
$ 44.11-7%New holding, 4651 sh.4,651
ALKSVanguard Health Care Fund 2013-12-31 Add0.1%$30.17 - $41.12
($36.93)
$ 44.1119%Add 28.18%3,672,087
ALKSVanguard Health Care Fund 2013-09-30 Add0.07%$28.66 - $35.35
($32.58)
$ 44.1135%Add 26.21%2,864,896
ALKSJoel Greenblatt 2013-09-30 Sold Out -0.03%$28.66 - $35.35
($32.58)
$ 44.1135%Sold Out0
ALKSVanguard Health Care Fund 2013-06-30 Add0.11%$22.35 - $33.72
($29.15)
$ 44.1151%Add 84.09%2,269,902
ALKSJoel Greenblatt 2013-06-30 Buy 0.03%$22.35 - $33.72
($29.15)
$ 44.1151%New holding, 26624 sh.26,624
ALKSVanguard Health Care Fund 2013-03-31 Add0.04%$18.52 - $23.81
($21.87)
$ 44.11102%Add 47.24%1,233,024
ALKSVanguard Health Care Fund 2012-03-31 Buy 0.07%$16.14 - $19.5
($16.48)
$ 44.11168%New holding, 787900 sh.787,900
ALKSJohn Burbank 2012-03-31 Sold Out -0.23%$16.14 - $19.5
($16.48)
$ 44.11168%Sold Out0
ALKSDaniel Loeb 2010-06-30 Sold Out -0.92%$10.7 - $13.75
($12.33)
$ 44.11258%Sold Out0
ALKSDaniel Loeb 2010-03-31 Buy 0.92%$9.41 - $14.01
($11.62)
$ 44.11280%New holding, 1000000 sh.1,000,000
ALKSGeorge Soros 2010-03-31 Sold Out $9.41 - $14.01
($11.62)
$ 44.11280%Sold Out0
ALKSJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$9.41 - $14.01
($11.62)
$ 44.11280%Sold Out0
ALKSGeorge Soros 2009-12-31 Buy $7.58 - $9.88
($8.72)
$ 44.11406%New holding, 22800 sh.22,800
ALKSDaniel Loeb 2009-12-31 Sold Out -0.37%$7.58 - $9.88
($8.72)
$ 44.11406%Sold Out0
ALKSDaniel Loeb 2009-09-30 Buy 0.37%$8.75 - $11.65
($10.13)
$ 44.11335%New holding, 500000 sh.500,000
ALKSJean-Marie Eveillard 2009-09-30 Buy 0.01%$8.75 - $11.65
($10.13)
$ 44.11335%New holding, 100000 sh.100,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALKS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ALKS John Burbank 2014-03-314,65100.01New Buy
ALKS Vanguard Health Care Fund 2014-03-315,180,2383.580.64+41.07%
Premium Most recent portfolio changes are included for Premium Members only!


ALKS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FRATES JAMES MSVP & CFO, Alkermes plc 2014-07-16Sell8,000$46.5-3.35view
FRATES JAMES MSVP & CFO, Alkermes plc 2014-07-09Sell7,000$47.41-5.21view
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc. 2014-07-09Sell16,667$47.41-5.21view
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc. 2014-07-03Sell7,000$51.31-12.41view
POPS RICHARD FDirector and CEO, Alkermes plc 2014-07-02Sell50,000$51.69-13.06view
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc. 2014-07-01Sell16,000$46.49-3.33view
MITCHELL PAUL JDirector 2014-07-01Sell1,000$50.57-11.13view
BREYER ROBERT ADirector 2014-07-01Sell5,000$50.57-11.13view
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc. 2014-06-30Sell8,475$50.26-10.58view
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc. 2014-06-26Sell10,000$49.92-9.98view

Press Releases about ALKS :

Quarterly/Annual Reports about ALKS:

News about ALKS:

Articles On GuruFocus.com
wait for positive ea Apr 06 2013 
comment on ALKS Mar 09 2013 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
Opportunistic Coat-tailing Jan 05 2010 


More From Other Websites
Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results Jul 24 2014
Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results Jul 24 2014
Alkermes' Pipeline Development Impresses, Key Updates Ahead Jul 21 2014
Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple... Jul 17 2014
Alkermes announces initiation of Phase 1 study of ALKS 8700 for treatment of MS Jul 17 2014
Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple... Jul 17 2014
Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates Jul 09 2014
Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates Jul 09 2014
Momentum names slammed as volatility comes back Jul 08 2014
Alkermes plc (ALKS) Jumps: Stock Rises 5.7% Jun 23 2014
Alkermes' Aripiprazole Lauroxil Looks Promising Jun 19 2014
New Alkermes Schizophrenia Drug -- An Important Advance With Social Benefits Jun 18 2014
Alkermes presents aripiprazole lauroxil phase 3 data Jun 18 2014
Alkermes Progresses with its Late Stage Candidate Jun 11 2014
Alkermes announces initiation of FORWARD-3, FORWARD-4 efficacy studies Jun 10 2014
Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for... Jun 10 2014
Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for... Jun 10 2014
What's in a Name? Alkermes Thinks Alkeus is too Close for Comfort Jun 09 2014

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide